Issue Date | Title | Author(s) |
2012-01-01 | Analyzing phase III studies in hospice/palliative care. A solution that sits between intention-to-treat and per protocol analyses: The palliative-modified ITT analysis | Currow, DC; Plummer, JL; Kutner, JS; Samsa, GP; Abernethy, AP |
2016-11-01 | Anticholinergic Drug Burden in Noncancer Versus Cancer Patients Near the End of Life | Hochman, MJ; Kamal, AH; Wolf, SP; Samsa, GP; Currow, DC; Abernethy, AP; LeBlanc, TW |
2019-05-01 | Anticholinergic Drug Burden in Noncancer Versus Cancer Patients Near the End of Life (vol 52, pg 737, 2016) | Hochman, MJ; Kamal, AH; Wolf, SP; Samsa, GP; Currow, DC; Abernethy, AP; LeBlanc, TW |
2013-03-01 | Delivery strategies to optimize resource utilization and performance status for patients with advanced life-limiting illness: Results from the "palliative care trial" [ISRCTN 81117481] | Abernethy, AP; Currow, DC; Shelby-James, T; Rowett, D; May, F; Samsa, GP; Hunt, R; Williams, H; Esterman, A; Phillips, PA |
2015-05-01 | Oxygen for relief of dyspnoea in people with chronic obstructive pulmonary disease who would not qualify for home oxygen: A systematic review and meta-analysis | Uronis, HE; Ekström, MP; Currow, DC; McCrory, DC; Samsa, GP; Abernethy, AP |
2015-01-01 | Practical Dyspnea Assessment: Relationship between the 0-10 Numerical Rating Scale and the Four-Level Categorical Verbal Descriptor Scale of Dyspnea Intensity | Wysham, NG; Miriovsky, BJ; Currow, DC; Herndon, JE; Samsa, GP; Wilcock, A; Abernethy, AP |
2015-05-01 | Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness a randomized clinical trial | Kutner, JS; Blatchford, PJ; Taylor, DH; Ritchie, CS; Bull, JH; Fairclough, DL; Hanson, LC; LeBlanc, TW; Samsa, GP; Wolf, S; Aziz, NM; Currow, DC; Ferrell, B; Wagner-Johnston, N; Zafar, SY; Cleary, JF; Dev, S; Goode, PS; Kamal, AH; Kassner, C; Kvale, EA; McCallum, JG; Ogunseitan, AB; Pantilat, SZ; Portenoy, RK; Prince-Paul, M; Sloan, JA; Swetz, KM; Von Gunten, CF; Abernethy, AP |
2012-01-01 | Understanding the impact of withdrawing from phase III studies in palliative care: Reply to Johnson et al. | Currow, DC; Samsa, GP; Abernethy, AP |